Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.

Pharmacotherapy - 1 Oct 2025

Jeong Eugene, Shendre Aditi, Su Yu, Guo Xingyi, Li Lang, Chen You

Abstract excerpt

BACKGROUND: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear. AIMS: This study leveraged...

Topics

Join the communities discussing this publication.

Case-Control Studies
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP3A
Drug Interactions
Fluconazole

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Muscular Diseases

Proton Pump Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40916919
DOI: 10.1002/phar.70058
PMCID: PMC12530008

Genes

CYP2C19
CYP3A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.PMID 40916919Read ↗

Statin myotoxicity: a review of genetic susceptibility factors.Semantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.Semantic proximity Read ↗

Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro.Semantic proximity Read ↗

Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.Semantic proximity Read ↗

Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome .Semantic proximity Read ↗

The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence.Semantic proximity Read ↗

Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.Semantic proximity Read ↗

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.Semantic proximity Read ↗

Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.Semantic proximity Read ↗

Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.Semantic proximity Read ↗

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.